Incidence and factors associated with adverse drug reactions in a cohort of individuals starting dolutegravir or efavirenz
DOI:
https://doi.org/10.33448/rsd-v11i4.26250Keywords:
Drug-related side effects and adverse reactions; Antiretroviral therapy, highly active; HIV; Dolutegravir; Efavirenz.Abstract
Prospective cohort of people living with HIV who started combination antiretroviral therapy (cART) with regimens containing efavirenz (EFV) or dolutegravir (DTG) in three specialized HIV/AIDS care services in Belo Horizonte, Brazil, with the objective of analyzing incidence, time to development and factors associated with the first adverse drug reaction (ADR). Data were collected from September 2015 to October 2018 through face-to-face interviews, clinical records, and information systems. The ADR-associated factors were evaluated with Cox regression and the time to the first ADR with Kaplan-Meier survival curves. Among the 433 individuals included, 217 (50.1%) had ADR in 12 months of follow-up. Among the 695 registered ADRs, 604 (86.9%) occurred in individuals using the EFV-based regimen, and gastrointestinal, psychiatric, and nervous system disorders were the most frequent. The mean time to develop the first ADR was 210.6 days (95% CI: 195.5-225.8). The concomitant use of other medications was associated with a higher risk of ADR (HR: 2.00; 95% CI: 1.38-2.89). The use of alcohol (HR: 0.64; 95% CI: 0.49-0.85) and the DTG-based regimen (HR: 0.40; 95% CI: 0.28-0.58) were factors associated with a lower risk of ADRs. We conclude that the DTG-based regimen had a better safety profile than the EFV-based regimen at 12 months of follow-up. Clinical and behavioral characteristics were associated with higher ADR risks and should be monitored when managing the treatment of HIV.
References
Antiretroviral Therapy Cohort Collaboration (2008). Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (London, England), 372(9635), 293–299. https://doi.org/10.1016/S0140-6736(08)61113-7
Associação Brasileira de Empresas de Pesquisa - ABEP (2008). Critério de classificação econômica. http://www.abep.org.
Batista, C.J.B, Correa, R. G., Evangelista, L. R., Fleck, K., Silva, L., Renaud, F., Vitoria, M., Doherty, M., & Benzaken, A. S. (2019). The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. Medicine, 98(10), e14828. https://doi.org/10.1097/MD.0000000000014828
Bertrand, L., Velichkovska, M., & Toborek, M. (2021). Cerebral Vascular Toxicity of Antiretroviral Therapy. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology, 16(1), 74–89. https://doi.org/10.1007/s11481-019-09858-x
Cardoso, T. S., Costa, J. O., Reis, E. A., Silveira, M. R., Bonolo, P. F., Santos, S., & Ceccato, M. (2019). Which antiretroviral regimen is associated with higher adherence in Brazil? A comparison of single, multi, and dolutegravir-based regimens. Cadernos de saude publica, 35(9), e00115518. https://doi.org/10.1590/0102-311X00115518
Carvalho, P. P., Barroso, S. M., Coelho, H. C., & Penaforte, F. (2019). Factors associated with antiretroviral therapy adherence in adults: an integrative review of literature. Fatores associados à adesão à Terapia Antirretroviral em adultos: revisão integrativa de literatura. Ciencia & saude coletiva, 24(7), 2543–2555. https://doi.org/10.1590/1413-81232018247.22312017
Centers for Disease Control and Prevention – CDC (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 41(RR-17):1-19 https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm
Chowta, M.N., Kamath, P., Ramapuram, J.T., Ashok Shenoy, K., Hadigal S. (2018) Evaluation of Adverse Drug Reaction Profile of Drugs Used as First-Line Antiretroviral Therapy. Interdisciplinary Perspectives on Infectious Diseases. 20188095609. https://doi.org/10.1155/2018/8095609
Dai, L., Su, B., Liu, A., Zhang, H., Wu, H., Zhang, T., Shao, Y., Li, J., Ye, J., Bai, S., Guo, X., & Sun, L. (2020). Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy. BMC infectious diseases, 20(1), 158. https://doi.org/10.1186/s12879-020-4878-2
de Oliveira-Filho, A. D., Morisky, D. E., Neves, S. J., Costa, F. A., & de Lyra, D. P., Jr (2014). The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Research in social & administrative pharmacy: RSAP, 10(3), 554–561. https://doi.org/10.1016/j.sapharm.2013.10.006
Fernández-Bargiela, N., Rotea-Salvo, S., Margusino-Framiñán, L., Balboa-Barreiro, V., Martín-Herranz, I., Castro-Iglesias, Á., Mena-De-Cea, Á., López-Calvo, S., Vázquez-Rodríguez, P., Míguez-Rey, E., & Cid-Silva, P. (2020). Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. European journal of hospital pharmacy: science and practice, ejhpharm-2020-002374. Advance online publication. https://doi.org/10.1136/ejhpharm-2020-002374
Ford, N., Shubber, Z., Pozniak, A., Vitoria, M., Doherty, M., Kirby, C., & Calmy, A. (2015). Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of acquired immune deficiency syndromes (1999), 69(4), 422–429. https://doi.org/10.1097/QAI.0000000000000606
Gutiérrez-Valencia, A., Viciana, P., Palacios, R., Ruiz-Valderas, R., Lozano, F., Terrón, A., Rivero, A., López-Cortés, L. F., & Sociedad Andaluza de Enfermedades Infecciosas (2009). Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Annals of internal medicine, 151(3), 149–156. https://doi.org/10.7326/0003-4819-151-3-200908040-00127
HIV-CAUSAL Collaboration, Ray, M., Logan, R., Sterne, J. A., Hernández-Díaz, S., Robins, J. M., Sabin, C., Bansi, L., van Sighem, A., de Wolf, F., Costagliola, D., Lanoy, E., Bucher, H. C., von Wyl, V., Esteve, A., Casbona, J., del Amo, J., Moreno, S., Justice, A., Goulet, J., … Hernán, M. A. (2010). The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (London, England), 24(1), 123–137. https://doi.org/10.1097/QAD.0b013e3283324283
Hoffmann, C., & Llibre, J. M. (2019). Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors. AIDS reviews, 21(1), 4–10. https://doi.org/10.24875/AIDSRev.19000023
Kanters, S., Vitoria, M., Zoratti, M., Doherty, M., Penazzato, M., Rangaraj, A., Ford, N., Thorlund, K., Anis, P., Karim, M. E., Mofenson, L., Zash, R., Calmy, A., Kredo, T., & Bansback, N. (2020). Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine, 28, 100573. https://doi.org/10.1016/j.eclinm.2020.100573
Kibret, G.D., Ayele, T.A., Tesfahun, A. (2019) Incidence and Predictors of Sever Adverse Drug Reactions Among Patients on Antiretroviral Therapy at Debre Markos Referral Hospital, Northwest Ethiopia. Research Square. https://doi.org/ 10.21203/rs.2.9264/v2.
Kindie, E., Alamrew Anteneh, Z., & Worku, E. (2017). Time to development of adverse drug reactions and associated factors among adult HIV positive patients on antiretroviral treatment in Bahir Dar City, Northwest Ethiopia. PloS one, 12(12), e0189322. https://doi.org/10.1371/journal.pone.0189322
Kumar, S., Rao, P. S., Earla, R., & Kumar, A. (2015). Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert opinion on drug metabolism & toxicology, 11(3), 343–355. https://doi.org/10.1517/17425255.2015.996546
Le Daré, B., Lagente, V., & Gicquel, T. (2019). Ethanol and its metabolites: update on toxicity, benefits, and focus on immunomodulatory effects. Drug metabolism reviews, 51(4), 545–561. https://doi.org/10.1080/03602532.2019.1679169
Maintenance and Support Services Organization- MSSO (2021). Medical dictionary for regulatory activities (MedDRA) v.24.0. http://www.meddramsso.com/
Masenyetse, L. J., Manda, S. O., & Mwambi, H. G. (2015). An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa. AIDS research and therapy, 12, 6. https://doi.org/10.1186/s12981-015-0044-0
Mendes, J. C., Bonolo, P. F., Ceccato, M., Costa, J. O., Reis, A., Dos Santos, H., & Silveira, M. R. (2018). Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy. European journal of clinical pharmacology, 74(8), 1077–1088. https://doi.org/10.1007/s00228-018-2472-y
Molina, J. M., Clotet, B., van Lunzen, J., Lazzarin, A., Cavassini, M., Henry, K., Kulagin, V., Givens, N., de Oliveira, C. F., Brennan, C., & FLAMINGO study team (2015). Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. The lancet. HIV, 2(4), e127–e136. https://doi.org/10.1016/S2352-3018(15)00027-2
Mudigubba, M.K., Murthy, M.K., Swaroop, A.M., M. N and Dahiya S. (2018) A systematic review of risk factors of adverse drug reactions in hospitalized patients. Asian Journal of Pharmaceutical and Clinical Research. 11(10):25-29. https://doi.org/10.22159/ajpcr.2018.v11i10.27759
Nickel, K., Halfpenny, N., Snedecor, S. J., & Punekar, Y. S. (2021). Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC infectious diseases, 21(1), 340. https://doi.org/10.1186/s12879-021-06016-8
Patel, D. A., Snedecor, S. J., Tang, W. Y., Sudharshan, L., Lim, J. W., Cuffe, R., Pulgar, S., Gilchrist, K. A., Camejo, R. R., Stephens, J., & Nichols, G. (2014). 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. PloS one, 9(9), e105653. https://doi.org/10.1371/journal.pone.0105653
Pimentel, G. S., Ceccato, M., Costa, J. O., Mendes, J. C., Bonolo, P. F., & Silveira, M. R. (2020). Quality of life in individuals initiating antiretroviral therapy: a cohort study. Revista de saude publica, 54, 146. https://doi.org/10.11606/s1518-8787.2020054001920
Sherfa, A., Haile, D., Yihune, M., & Sako, S. (2021). Incidence and predictors of Adverse Drug Reaction (ADR) among adult HIV positive patients on anti-retroviral treatment in Arba Minch town public health facilities, southern Ethiopia: A retrospective cohort study, 2020. PloS one, 16(5), e0251763. https://doi.org/10.1371/journal.pone.0251763
Shet, A., Antony, J., Arumugam, K., Kumar Dodderi, S., Rodrigues, R., & DeCosta, A. (2014). Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India. PloS one, 9(3), e91028. https://doi.org/10.1371/journal.pone.0091028
Siefried, K. J., Mao, L., Cysique, L. A., Rule, J., Giles, M. L., Smith, D. E., McMahon, J., Read, T. R., Ooi, C., Tee, B. K., Bloch, M., de Wit, J., Carr, A., & PAART study investigators (2018). Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. AIDS (London, England), 32(1), 35–48. https://doi.org/10.1097/QAD.0000000000001685
Taha, H., Das, A., & Das, S. (2015). Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS. Infection and drug resistance, 8, 339–352. https://doi.org/10.2147/IDR.S68396
Walmsley, S., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, E., Khuong-Josses, M. A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., Roth, N., Wong, D., Granier, C., Wynne, B., & Pappa, K. (2015). Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. Journal of acquired immune deficiency syndromes (1999), 70(5), 515–519. https://doi.org/10.1097/QAI.0000000000000790
World Health Organization - WHO (1972). International drug monitoring: the role of national centres. Tech Rep Series WHO 1972, no 498.
World Health Organization - WHO (2020). Guidelines for ATC classification and DDD assignment 2020. https://www.whocc.no/atc_ddd_index/.
Yombi J. C. (2018). Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect. AIDS reviews, 20(1), 14–26.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Jullye Campos Mendes; Maria das Graças Braga ; Adriano Max Moreira Reis; Micheline Rosa Silveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
